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Summary Epidermal tumourigenesis can be achieved in rodents by the application of a single subthreshold
dose of a carcinogen (initiation) followed by repeated applications of a tumour promoter such as 12-0-
tetradecanoyl phorbol, 13-acetate (TPA). TPA induces terminal differentiation in the majority of epidermal
keratinocytes in vitro. However, transformed keratinocytes respond weakly to this terminal differentiation
signal, and it is suggested that this property allows initiated cells and their progeny to obtain a selective
advantage over their normal counterparts during promotion ofpapilloma formation by TPA.
New data are reviewed which suggest that a putative wound hormone TGF-P has similar differential effects
on normal and transformed epithelial cells to those of TPA. It is proposed that the release of TGF-,B from
platelets following deep skin wounding may be an explanation as to why wounding is a promoting stimulus
but milder forms of epidermal injury are not. Weakly promoting hyperplasiogenic agents are also discussed
within the context of a selection theory of tumour promotion.
The two stage (initiation-promotion) system of
epidermal tumourigenesis is achieved by a single
application of a subthreshold (initiating) dose of a
carcinogen (usually DMBA) followed by repeated
applications of a tumour promoter such as 12-0-
tetradecanoyl phorbol, 13-acetate (TPA). This
method of inducing epidermal tumours has been
reviewed many times (see Boutwell 1964; Stenback
et al., 1974; Scribner & Suss 1978; Boutwell et al.,
1982) and is applicable to many strains of mice (Di
Giovanni et al., 1984, and references therein),
Sprague-Dawley rats (Schweizer et al., 1982) and
European hamsters (Goerttler et al., 1984).
How TPA and other manipulations of the skin
such as wounding (Hennings & Boutwell 1970;
Clark-Lewis & Murray, 1978) or deep epidermal
abrasion (Argyris 1980a) promote the growth of an
initiated cell into a tumour has until recently
remained obscure. The purpose of this review is to
evaluate evidence supporting the suggestion (Yuspa
et al., 1981) that TPA stimulates the development
of tumours by selecting for keratinocytes which
have acquired a reduced response to terminal differ-
entiation signals as a result of initiation (Yuspa &
Morgan, 1981). The application of this selection
hypothesis to other promoting stimuli, particularly
physical injury will also be discussed.
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1. Two-stage epidermal tumourigenesis
The initiation-promotion protocol produces pri-
marily clonal benign papillomas (Iannacone et al.,
1978; Reddy & Fialkow, 1983), the majority of
which are promoter-dependent lesions, (i.e. their
growth is reversible) although the probability that
the papillomas will become autonomously growing
and develop into carcinomas increases with the
duration of promoter treatment (Burns et al., 1978;
Verma & Boutwell, 1980).
TPA itself does not detectably increase the
conversion rate of papillomas into carcinomas
(Burns et al., 1978; Verma & Boutwell, 1980;
Hennings et al., 1983) and at certain doses actually
decreases it (Verma & Boutwell, 1980). The
inability of TPA to enhance malignant conversion
may be related to its inactivity as a mutagen in
mammalian cells (Trosko et al., 1977) since
Hennings et al. (1983) have shown that carcino-
matous transformation is enhanced by initiators
suggesting that further gene mutations are required
to complete carcinogenesis.
By the use of croton oil as a first stage promoter
and turpentine as a second stage promoter,
Boutwell (1964) was able to subdivide the
promotion phase, and he termed the two stages
conversion and propagation, respectively.
Unfortunately, probably because of the inconsistent
composition of turpentine preparations these results
were not readily reproducible (Raick, 1974; Slaga et
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al., 1975). However, in the last few years the use of
TPA as a stage I promoter and mezerein (Slaga et
al., 1980a,b) or 12-0-retinoylphorbol-13 acetate
(RPA-Furstenberger et al., 1981; 1983) as the stage
II promoter, it has been possible to demonstrate
two qualitatively different stages of promotion
using pure compounds. Stage I can be achieved by
as little as one treatment with TPA (Slaga et al.,
1980b; Furstenberger et al., 1983) and is longer
lasting than stage II which requires multiple
treatments before the papillomas appear.
2. The genetic and phenotypic nature of the initiation
event
Provided that appropriate corrections are made for
mouse ageing, the initiation event can be
demonstrated to be irreversible for at least a year
(Van Duuren et al., 1975; Loehrke et al., 1983)
suggesting that initiation involves a permanent
change in the keratinocyte genome. Also since
treatments of the epidermis which increase kera-
tinocyte division in the absence of damage (e.g. skin
massage) do not cause papilloma development in
initiated skin (Clark-Lewis & Murray, 1978; Marks
et al., 1979) the initiation event is generally held to
be phenotypically silent (Boutwell, 1974; Boutwell
et al., 1982). However, there is evidence that if the
gap between initiation and the beginning of
promotion is increased from the usual two weeks to
10-40 weeks, the latent period between the
commencement of promotion and the appearance
of the first papillomas is reduced (Berenblum &
Shubik, 1947, Boutwell, 1964; Hennings &
Boutwell, 1967; Van Duuren et al., 1967, 1975;
Loehrke et al., 1983), and this could indicate that
the initiated cells are capable of limited clonal
expansion without promoter treatment (see
Hennings and Yuspa, 1985).
Recent experiments by Yuspa and Morgan (1981)
have shed some light on the possible phenotype of
the initiated cell. In these experiments mouse skin
was initiated in vivo and after 2 weeks the keratino-
cytes were placed in culture in medium containing
low (<0.1 mM) calcium where the cells maintain
basal cell characteristics (Hennings et al., 1980) and
remain as a monolayer. When these cultures were
switched to medium containing high calcium
(1.2mM) after an expression time of 11 weeks, the
normal keratinocytes stratified, differentiated and
sloughed from the dish, and staining of the plates
revealed foci of keratinocytes resistant to calcium-
induced terminal differentiation only in cultures
prepared from initiated animals (Yuspa & Morgan,
1981). Furthermore, TPA treatment of the initiated
mice prior to placing the keratinocytes in culture
resulted in an increase in the number of plates
containing foci, significantly demonstrating that
TPA had given the differentiation - resistant kera-
tinocytes a selective advantage over their normal
counterparts in vivo, an observation which is
consistent with their being progeny of the initiated
cells.
Even more recently, a candidate for the genomic
target in keratinocyte initiation has emerged
following the reports by Balmain and co-workers
that genes related to the Harvey Murine Sarcoma
Virus capable of transforming NIH 3T3 cells (rasH)
can be rescued from both carcinomas (Balmain &
Pragnell, 1983) and papillomas (Balmain et al.,
1984) generated by the two stage protocol. Several
of these 'activated' ras1 genes have been analysed
and found to have mutations in either codon 12 or
codon 61, furthermore the resulting mutant
proteins can be distinguished from the normal rasH
gene product by polyacrylamide gel electrophoresis
(Balmain, 1985). Additionally, Balmain and co-
workers have shown that rasH delivered in its viral
vector can mimic initiation in vivo, as no papillomas
appear after infection of mouse skin with the
Harvey Murine Sarcoma Virus alone but do so
when TPA is repetitively applied (A. Balmain -
personal communication).
In vitro, ras-containing viruses can block
keratinocyte differentiation at an early stage of
maturation (Yuspa et al., 1983a; 1985) but the cells
cannot proliferate very well when a differentiation
stimulus is applied in the absence of TPA (Yuspa et
al., 1985). When TPA is applied proliferation
results and Yuspa et al. (1985) interpret these
findings as indicating that rasH activation could
initiate the keratinocytes in vivo as the virus-
infected cells do not grow well in the absence of
TPA (a characteristic of promoter-dependent
papillomas).
These two latter studies suggest that although
other oncogenes may sometimes be involved,
alteration of the rasH gene is capable of initiating
mouse epidermal carcinogenesis. However, both
studies used rasH delivered in the viral vector,
which unlike the activated genes found in epidermal
tumours (Balmain & Pragnell, 1983; Balmain et al.,
1984) differs from the normal cellular homologue in
more than one transforming codon and is also
preceded by a long terminal repeat sequence which
may increase gene expression (see Duesberg, 1983,
for a review). Therefore, keratinocytes infected with
Harvey Murine Sarcoma Virus might reflect the
behaviour of keratinocytes at a later stage of
neoplastic progression which have acquired other
modifications of the rasH gene beyond those
required for the initiation step. Indeed, Spandidos
and Wilkie (1984) have reported that a mutated
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fibroblasts in a single step but only if its expression
is increased. Also, Balmain et al. (1984) have
reported increased rasH expression in epidermal
papillomas. Therefore, whilst much progress has
recently been made, further work is necessary to
fully elucidate the nature of the genomic alteration
associated with the initiation of epidermal carcino-
genesis.
3. The morphological and biochemical effects of
TPA on mouse dorsal epidermis
The first TPA treatment causes considerable loss of
basal cells and an increase in the number of supra-
basal cells (Argyris, 1980b; Reiners & Slaga, 1983).
In some cases the epidermis may become separated
from the dermis (Argyris, 1980b) and psoriasis-like
scaling of the skin sometimes occurs (Furstenberger
et al., 1985). The changes are the likely result of the
ability of TPA to induce terminal differentiation in
the majority of epidermal keratinocytes (Steinert &
Yuspa, 1978; Yuspa et al., 1980; 1982; Hawley-
Nelson et al., 1982; Parkinson & Emmerson, 1982;
Mufson et al., 1982; Reiners & Slaga, 1983). The
loss of basal cells is followed by a peak of DNA
synthesis at 30h (Kreig et al., 1974) and a peak of
mitosis at 2 days (Argyris, 1980b). The increased
rates of division are achieved by a reduction in the
cell cycle time of the growth fraction from between
5 and 7 days before TPA treatment to - 16h at the
peak of TPA induced proliferation. The increased
rate of cell division is accompanied by a reduction
in the epidermal transit time from 8 days before
TPA treatment to 2 days at the peak of stimulation
(Morris & Argyris, 1983). At some stage cell
production must temporarily exceed cell loss so that
in combination with the above changes a thickening
of all the epidermal layers is produced (hyper-
plasia), and the kinetic data suggest that it is
largely the result of extensive tissue regeneration
similar to that which follows epidermal damage
(Argyris, 1980a,b).
As most tumour promoters are hyperplasiogenic
(Frei & Stephens, 1968) hyperplasia would appear
to be crucial for tumour promotion. This is further
supported by the study of TPA-induced promotion
in different species displaying varying hyperplasia
after repeated TPA treatments, where there was
generally a good correlation between the ability of
TPA to promote tumours and its ability to produce
a sustained epidermal hyperplasia (Sisskin &
Barrett, 1981; Sisskin et al., 1982). The exception
was the DBA/2 mouse strain which responded to
TPA with a good sustained hyperplasia and a low
tumour yield (Sisskin et al., 1982). However, this
anomaly was recently shown to be due to inefficient
initiation of this species by the dose of DMBA used
by Sisskin and colleagues and if the correct dose of
DMBA, or a different initiator such as MNNG was
used, then DBA/2 mice responded to promotion by
TPA with a high tumour yield (Di Giovanni et
al., 1984) as predicted from their hyperplastic
response (Sisskin et al., 1982). Furthermore, it has
recently been shown that neonatal mice which are
refractory to TPA-induced hyperplasia (Bertsch &
Marks, 1974) are also refractory to stage I
promotion by TPA (Furstenberger et al., 1985) and
these refractory conditions subside in parallel as the
adult pattern of epidermal differentiation appears
(Furstenberger et al., 1985). Stage I promotion has
also been directly shown to require DNA synthesis
(Kinzel et al., 1984a). Taken together these studies
indicate that epidermal hyperplasia or an event
closely associated with it, is important for the
completion of both stage I and stage II promotion,
and this is supported by the work of Slaga et al.
(1980a) who reported that steroids [potent
inhibitors of epidermal hyperplasia (Belman &
Troll, 1972; Scribner & Slaga, 1973; Schwarz et al.,
1977)] were potent inhibitors of both stage I and
stage II promotion in SENCAR mice.
Epidermal hyperplasia is accompanied by
increased synthesis of prostaglandins, enhanced
ornthine decarboxylase and phosphodiesterase
activities, refractoriness to catecholamines,
desensitization to epidermal G1 chalone (for a
review see Marks et al., 1982) and the appearance
of morphologically distinct dark cells (Raick, 1973;
Klein-Szanto et al., 1980) thought by some to be
primitive stem cells. Of these changes the synthesis
of prostaglandin E2 has been demonstrated to be
crucial for the hyperplastic transformation of the
epidermis as when its synthesis is blocked by
inhibitors of cycloxygenase (Verma et al., 1980) or
arachidonic acid metabolism (Fischer et al., 1982a)
both hyperplasia (Verma et al., 1977; Furstenberger
& Marks, 1978), and tumour promotion (Slaga &
Scribner, 1973; Verma et al., 1977; 1980; Fischer et
al., 1982a) are prevented. Furthermore, the addition
of exogenous prostaglandin E2 to skin where
endogenous synthesis has been blocked results in a
restoration of hyperplastic reponse (Verma et al.,
1980; Furstenberger & Marks, 1978; Marks et al.,
1981) though curiously not tumour promotion, the
latter being partially restored by the addition of
exogenous prostaglandin F2 which does not restore
hyperplasia (Marks et al., 1982). The latter authors
have suggested that prostaglandin F2. may be
involved in an event that is absolutely essential for
promotion, whilst prostaglandin E2 mediated
proliferation and hyperplasia play only a permissive
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In line with this, whilst the above changes
brought about by TPA are also brought about by
certain kinds of epidermal injury such as wounding
and full thickness abrasion which are also
promoting stimuli (Hennings & Boutwell, 1970;
Clark-Lewis & Murray, 1978; Argyris, 1980a) they
are also produced by non-promoting stimuli such as
mild abrasion by sandpaper rubbing (Marks et al.,
1979) and treatment of the skin with the calcium
ionophore, A23187 (Marks et al., 1981; Klein-
Szanto et al., 1982). Similarly, with the exception
of dark cell induction (Klein-Szanto et al., 1980,
1982) all the TPA-induced effects cited above are
produced with at least equal potency by the second
stage promoters mezerein (Mufson et al., 1979) and
RPA (Furstenberger et al., 1981).
This together with several other reports of non-
promoting hyperplasiogenic agents (Slaga et al.,
1975; Raick & Burdzy, 1973; Raick, 1974;
Hennings & Boutwell, 1970) might lead one to
conclude as many have done, that hyperplasia and
the biochemical changes associated with it are
necessary but insufficient conditions for promotion
(see for example, Slaga et al., 1975; Marks et al.,
1979; Mufson et al., 1979). It is therefore possible
that there are subtle differences in the manner in
which hyperplasia is brought about by some of
these epidermal manipulations which could account
for their being unable to promote tumour
development. I shall argue the case for this in the
next section.
4. TPA-induced keratinocyte terminal differentiation
and the selection of initiated cells
There are now many reports that normal keratino-
cyte differentiation in vitro (Steinert & Yuspa, 1978;
Yuspa et al., 1980, 1982; Hawley-Nelson et al.,
1982; Parkinson & Emmerson, 1982; Mufson et al.,
1982, Reiners & Slaga, 1983) and in vivo (Reiners &
Slaga, 1983) is accelerated by TPA. As stated
earlier (Section 2) colonies of keratinocytes which
fail to respond to terminal differentiation signals
can be detected in vitro following initiation of
mouse skin in vivo. Furthermore, their numbers are
increased following in vivo treatment with TPA
(Yuspa & Morgan, 1981). Although these
putatively initiated cells also gave rise to immortal
cell lines in vitro (Yuspa et al., 1983b), it was
suggested (Yuspa et al., 1981) that the initiated cells
grow into papillomas after TPA treatment because
unlike normal keratinocytes they would be resistant
to the induction of terminal differentiation by the
tumour promoter and would clonally expand into
the space left by the suprabasally migrating normal
keratinocytes (Argyris, 1980b; Reiners & Slaga,
1983) during the regenerative hyperplasia that
follows promoter treatment (Argyris, 1980b).
In support of these arguments it has now been
shown that cell lines derived from papillomas
(Parkinson et al., 1984), squamous cell carcinomas
(Parkinson & Emmerson, 1982; Parkinson et al.,
1983, 1984; Stanley et al., 1985; Willey et al., 1984)
keratinocytes transformed by viruses (Parkinson &
Emmerson, 1982; Parkinson et al., 1983; 1984;
Yuspa et al., 1985) and the progeny of putative
initiated cells (Yuspa et al., 1983b; Hennings et al.,
1984) are all refractory or less sensitive than normal
to TPA-induced terminal differentiation. Further-
more, we have shown that a non-tumourigenic
subclone of a skin carcinoma (cell line SCC-12F)
which responds normally to the terminal differen-
tiation stimulus of suspension culture (Rheinwald &
Beckett, 1980), also responds normally to TPA
(Parkinson et al., 1983, 1984) showing that the
defective response of transformed keratinocytes is
indeed due to a defect in their ability to respond to
terminal differentiation signals, and not to other
transformation events such as in vitro immortali-
sation for example.
If the defect possessed by the initiated cells and
their progeny enables them to selectively resist
terminal differentiation by TPA, then no such
selective resistance should be observed by non
promoting hyperplasiogens such as the calcium
ionophore, A23187 (Marks et al., 1981) or ethyl
phenyl propiolate (Raick & Burdzy, 1973). When
we tested these compounds on normal and
transformed keratinocytes in vitro we found that
the transformed keratinocytes lost their ability to
replicate (as assessed by loss of cloning ability) at
least as much as their normal counterparts
(Parkinson & Emmerson, 1984) and were in fact
five times more sensitive to A23187. This lack of
selectivity in favour of transformed keratinocytes
may therefore explain the failure of certain hyper-
plasiogenic chemicals as promoters in vivo whilst
others like acetic acid (Murray, 1978) and certain
doses of mezerein (Sharkey cited by Argyris, 1983)
may be so toxic that they kill the initiated cells
before they are promoted.
If these explanations are true for the failure of
certain hyperplasiogenic chemicals as promoters
how does the selection theory fit for other types of
epidermal manipulation? Why for example, does
wounding (Hennings & Boutwell, 1970; Clark-Lewis
& Murray, 1978) or deep abrasion (Argyris, 1980a)
promote tumours whereas milder forms of
epidermal manipulation (Clark-Lewis & Murray,
1978; Marks et al., 1979) do not. Marks et al.
(1982) have introduced the concept that a 'wound-
specific' response is crucial to tumour promotion by
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release of a 'wound-hormone' may be critical in the
former instance. There is now evidence for the
convergence of this idea with the selection theory of
Yuspa et al. (1981). A platelet-derived factor
(Lechner et al., 1983), recently characterised as
TGF-,B (C.C. Harris, personal communication),
stimulates differentiation and keratinization of
normal, but not transformed human bronchial
epithelial cells proliferating in a chemically defined
medium, in a very similar manner to TPA (Willey
et al., 1984), and hence might be expected to permit
the same type of selective advantage to the initiated
cells and their progeny if released in chemically
initiated skin. The reports that the effect of TGF-#
is synergistic with EGF to promote wound repair
(Sporn et al., 1983), and that it is found in platelets
(Childs et al., 1982; Assoian et al., 1983) and
clotted blood serum (Childs et al., 1982) but not
plasma (Childs et al., 1982), suggest that the release
of TGF-f may occur as part of the natural process
of wound healing following damage to blood
vessels. Blood vessel damage and the release of
TGF-,B would accompany the promoting stimuli of
skin wounding (Hennings & Boutwell, 1980; Clark-
Lewis & Murray, 1978; Marks et al., 1979) and to a
lesser extent deep abrasion (Argyris, 1980a), but
not the non-promoting stimuli of superficial
abrasion (Marks et al., 1979) or skin massage
(Clark-Lewis & Murray, 1978; Marks et al., 1979).
There is now good evidence that the membrane
receptor for TPA (Delclos et al., 1980) is protein
kinase C (Castagna et al., 1982). Protein kinase C is
normally activated by diacyglycerol which is
produced by the stimulation of phosphatidyl
inositol turnover following the interaction of certain
hormones or growth factors with their receptors
(see Nishizuka, 1984, for a review). As there is
evidence from other systems that the induction of
differentiation by TPA may involve protein kinase
C (Fuerstein & Cooper, 1984; Ebeling et al., 1985)
it is also possible that other hormones and growth
factors might be released during wounding to
activate the enzyme and like TPA give the keratino-
cytes a selective advantage. The same argument
applies to tumour promoters like teleocidin which
bind to the phorbol ester receptor (Umezawa et al.,
1981; Schmidt et al., 1983).
However, epidermal tumour promoters like
anthralin or benzoyl peroxide do not bind to
phorbol ester receptors (Delclos et al., 1980)
suggesting that their molecular mechanism of action
is different from that of TPA. This is further
substantiated by the observation that benzoyl
peroxide is an efficient promoter in mouse strains
where TPA is not (Reiners et al., 1984). Anthralin
and benzoyl peroxide do not produce the same
morphological effects as TPA in keratinocyte
cultures (Parkinson & Emmerson, 1982; Lawrence
et al., 1984) but benzoyl peroxide is reported to
induce cornification in other systems (Saladino et
al., 1985). Nevertheless, as the differential effect of
these compounds on normal and transformed
keratinocytes in vitro has not yet been examined the
application of the selection theory (Yuspa et al.,
1981; 1982; 1983b) to non-phorbol promoters
cannot be ruled out.
Diethylstilboestrol is a possible tumour promoter
in the human genital tract (Lillehaug & Djurhuus,
1982; Siegfried et al., 1984) and when Stanley et al.
(1985) studied its effects on cultured cervical
keratinocytes and their transformed counterparts,
the found it killed tumour cells rather more slowly
than normal keratinocytes perhaps indicating that
some non phorbol promoters are also selective for
transformed cells. However this would be a weak
effect compared to that produced by TPA (Stanley
et al., 1985).
5. Heterogeneity of the reponse of basal
keratinocytes to TPA-induced terminal
differentiation
It is thought that initiated cells have the phenotype
of normal cells (Boutwell, 1974, 1982) or that their
transformed character is greatly repressed (see
Hennings & Yuspa, 1985, and references therein).
This coupled with the observation that initiation is
essentially permanent suggests that initated cells are
stem cells or committed cells that have irreversibly
dedifferentiated into stem cells as a consequence of
initiation, because under normal circumstances the
stem cells are the only permanent residents of the
epidermis (see Potten, 1983, for a review). If
initiated cells have a normal phenotype however,
the simple version of the selection theory outlined
in section 4 is presented with a problem. If TPA
were to induce all phenotypically normal keratino-
cytes to differentiate with equal probability the first
promoter treatment would result in the loss through
terminal differentiation of many initiated cells
before they could be promoted. Whilst this may be
the case, it seems more likely that the loss of
initiated cells is avoided because they are contained
within a keratinocyte sub-population, which also
contains the stem cells, and which is refractory or
less sensitive to the induction of terminal
differentiation by TPA (see Yuspa et al., 1981).
Keratinocyte sub-populations have indeed been
reported in which TPA fails to inhibit DNA
synthesis and increase transglutaminase activity
(Yuspa et al., 1982, 1983b) or induce cornified
envelope and disulphide bond formation (Reiners &
Slaga 1983). Also we have found that when484 E.K. PARKINSON
keratinocyte cultures are treated with various doses
of TPA, a dose of 10 -8M is sufficient to eliminate
the replicative potential of most of the keratino-
cytes, but a small sub-population is resistant to
doses as high as 10- M (Parkinson et al., 1983;
1984). These TPAR keratinocytes are the precursor
population of the other clonogenic keratinocytes
and their differentiated progeny (Parkinson et al.,
1983), and show an inverse relationship with the
differentiated keratinocytes in a variety of
experimental situations (see Parkinson et al., 1984).
Yuspa et al., (1982, 1983b) have also described a
keratinocyte population which fails to respond to
TPA-induced terminal differentiation and which
regenerates the TPA-responsive population. We
have suggested that the TPAR keratinocytes are a
sub-population of clonogenic keratinocytes further
removed from terminal differentiation than the rest
(Parkinson et al., 1983; 1984) and Yuspa and co-
workers have argued along similar lines (Yuspa
et al., 1981, 1982, 1983b). Two main pieces of
evidence support these arguments.
When keratinocytes are separated into different
size classes on percoll gradients on the basis of their
bouyant density (Sun & Green, 1976) it can be
demonstrated that the smallest cells are the ones
furthest removed from terminal differentiation (Sun
& Green, 1976; Fischer et al., 1982b; Schweizer et
al., 1984). Exploiting this observation Reiners and
Slaga (1983) were able to show that markers of the
differentiated state appeared much more quickly in
the large mature keratinocytes than in the smaller
cells following the separation of mouse keratino-
cytes from skin treated in vivo with promoting
doses of TPA.
The second piece of evidence comes from a study
of the effect of TPA on basal cells at different
points in the keratinocyte lineage in vivo (Morris et
al., 1985). Mouse dorsal epidermis is composed of
numerous epidermal proliferative units (EPU) (see
Potten, 1983, for a review) which in turn are
composed of a central small group of 3-4 basal
cells surrounded by 6 or 7 other basal cells, all of
which are covered by a stack of 9 or 10 suprabasal
cells at various stages of maturation. (Figure 1). A
cell in the central subgroup is a likely candidate for
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the stem cell of the unit because of its strategic
position, slow cell cycle, rapid response to
wounding and because it is rarely seen to move
suprabasally, in contrast to the peripheral basal
cells of the unit (see Potten, 1983). If mouse
epidermis is labelled with [3H]TdR over a period of
7 days 95% of the basal cells are labelled (Morris et
al., 1985) but if the animals are left for one month
the labelling index drops to 2%. Ninety per cent of
the latter label-retaining cells (LRCs) as defined by
(Mackenzie & Bickenbach, 1982) were located
within a nuclear diameter of the central cell
position of the EPU (Morris et al., 1985). If the
central cell was the stem cell of the EPU it might
be expected to have a slower cell cycle time than
the peripheral committed cells dividing only once
for every two divisions of the latter, and this would
partly explain its label-retaining properties. In the
experiments of Morris et al. (1985) when mouse
skin was treated with a promoting dose of TPA
soon after the basal cells were labelled, most of the
labelled keratinocytes moved suprabasally in line
with earlier reports (Argyris, 1980b; Reiners &
Slaga, 1983) and with the observation that TPA
induces a terminal differentiation in the majority of
keratinocytes (Steinert & Yuspa, 1978; Yuspa et al.,
1980; 1982; Parkinson & Emmerson, 1982; Hawley-
Nelson et al., 1982; Mufson et al., 1982; Reiners &
Slaga, 1983). If treatment of the animals with TPA
was delayed for one month to allow a study of the
LRCs then these cells, the majority of which may
be stem cells, responded very differently. They
rarely moved suprabasally and divided at least once
within the 28h experimental period as evidenced by
the appearance of labelled mitoses (Morris et al.,
1985). Furthermore, it was possible to demonstrate
the persistance of some of the LRCs and their
progeny for at least 2 weeks after TPA treatment
suggesting that some of the LRCs were responsible
for the long term regeneration of the epidermis
following TPA-induced cell loss. If the LRCs are
stem cells and the initiated keratinocytes are
retained within this population then the induction
of terminal differentiation in the mature basal
keratinocytes coupled with the stimulation of stem
cell division (including the initiated ones) would
explain how essentially phenotypically normal
initiated cells would at first expand into a clone
(Yuspa et al., 1981; 1982; 1983b). Following this
the transformed phenotype would be expressed
(Slaga et al., 1980b; Furstenberger et al., 1983) and
the transformed cells would be then given a
selective advantage as outlined in section 4 (see
Figure 2). Whether the stem cells (and hence also
the initiated cells) are stimulated to divide directly
by TPA as suggested by Yuspa et al. (1981; 1982;
1983b) or indirectly as a consequence of the natural
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Figure 2 The clonal expansion of initiated cells and
their progeny.
response of the epidermal tissue to TPA-induced
injury (Argyris, 1980b) is not entirely certain. The
hypothesis of Yuspa et al. (1981; 1982; 1983b)
predicts that because initiated cells are blocked at
an early stage of differentiation (see also Yuspa et
al., 1985) they should proliferate in reponse to TPA
and remain refractory to the stimulus to
differentiate. Recent studies have shown however,
that whilst the second part of the prediction is
fulfilled in cultured initiated cell lines, their
proliferative response to TPA is variable (Hennings
et al., 1984). Regardless of the precise mechanism,
the observation that epidermal proliferation follows
TPA treatment of mouse skin in vivo, (Raick et al.,
1972) is consistent with the selection theory pro-
posed by Yuspa et al.
6. The selection theory and second stage promoters
At first because stage I of tumour promotion (see
section 1) was thought to be irreversible and could
be achieved by as little as one treatment with TPA486 E.K. PARKINSON
(Slaga et al., 1980b; Furstenberger et al., 1983), it
was suggested that TPA caused 'a permanent
alteration in the genetic readout of the initiated cell'
to complete stage I whereas subsequent TPA
treatments were only necessary to make the
dormant papilloma cells become visible (Fursten-
berger et al., 1983). However, the high efficiency by
which a single TPA treatment achieves stage I
promotion (40% of those initiated - Furstenberger
et al., 1981) suggested that a permanent genomic
change was unlikely to be involved, and recent data
showing stage I of promotion to be reversible, with
at most a half-life of 10 weeks (Slaga, 1983;
Furstenberger & Marks, personal communication),
supports this suggestion.
Yuspa et al. (1981) first introduced the concept
that second stage promoters might be toxic to the
initiated cells and have recently suggested that they
might be operative at a later stage because the dose
of the second stage promoter would most likely be
reduced at later times as a result of the hyperplastic
thickening of the epidermis. It was suggested that
this, coupled with the increased initiated clone size,
would afford protection against second-stage
promoter toxicity (Hennings & Yuspa, 1985). These
authors further suggested that stage I promotion
would be completed spontaneously by limited
clonal expansion of the initiated cells so that a
second-stage promoter (in this case, mezerein)
would be efficient as a complete promoter if its
application were delayed. They provided data which
supported their hypothesis but their ideas are
difficult to reconcile with the recent observation
that stage I promotion is reversible even when
brought about by TPA treatment (Slaga, 1983)
whereas the clonal expansion following initiation is
not (Loehrke et al., 1983). However, the suggestion
that second stage promoters may be more
damaging to the initiated cells than TPA is
supported by the observations that they inhibit
tumour promotion by TPA when applied before it
(Sharkey cited by Argyris, 1983) or together with it
(Slaga et al., 1980b). Furthermore, the TPAR
population in keratinocyte cultures which is similar
to the stem cell population in vivo as regards its
response to TPA (and hence might be
representative of the initiated cells - see section 5)
is very sensitive to both mezerein and RPA
(Parkinson et al., 1984; Stanley et al., 1985).
Similarly, preliminary reports suggest that the label-
retaining putative stem cells (Mackenzie &
Bickenbach, 1982) are not stimulated to divide by
either mezerein (McCutcheon et al., 1984) or RPA
(McCutcheon et al., 1985) in contrast to their
stimulation by TPA (Morris et al., 1985). Dark cells
thought by some to primitive keratinocytes (Raick,
1973) are also observed in relatively fewer numbers
in mezerein-treated, as opposed to TPA-treated
Sencar mouse skin (Klein-Szanto et al., 1980; 1982)
and there is evidence that dark cell induction is a
good indicator of stage I promoting power in this
system (Klein-Szanto et al., 1982; Slaga et al.,
1980a). The apparent toxic action of second stage
promoters may result from their ability to induce
terminal differentiation in all the basal cells equally
whereas TPA appears to preferentially affect the
more mature population (Parkinson et al., 1983;
1984; Morris et al., 1985).
Nevertheless, the observations that RPA at the
10nmol dose- used by Furstenberger and co-
workers (Furstenberger et al., 1981, 1983) is not
toxic to the initiated cells (Kinzel et al., 1984a) and
that RPA is 10-fold less potent at inhibiting DNA
synthesis in HeLa cells (Kinzel et al., 1984b) suggest
that second-stage promoters fail as complete pro-
moters because at low doses they do not fulfil a
vital function necessary for the completion of stage
I promotion, but that when the dose is increased to
a level where stage I could be completed they are
toxic to the initiated cells and so few papillomas
still result (Parkinson et al., 1984). Additional
evidence that there are indeed two qualitatively
different stages in promotion comes from the
observations that the two stages are inhibited by
different antagonists (Slaga et al., 1980a) and are
dependent to different extents on the synthesis of
prostaglandins F2a and E2 (Fustenberger & Marks,
personal communication). This suggests that the
two stages have a different molecular basis.
Furthermore, the argument that the second stage
promoters fail to promote because they are
generally toxic is also not supported by our
observation that cell lines from papillomas and
carcinomas respond to second stage promoters and
TPA in a similar fashion (Parkinson et al., 1984;
Stanley et al., 1985). Additionally, transformed cell
lines are sensitive to the toxic effects of the second
stage promoters if the defective response to a
differentiation signal is not expressed, as is the case
with the non-tumourigenic subclone F of carcinoma
line SCC-12 (Parkinson et al., 1984).
Taken together the above data suggest that
toxicity may play a part in the failure of RPA and
mezerein to promote tumours but that full
phenotypic expression of the defective response to
inducers of terminal differentiation may also be
associated with the early TPA treatments. Whilst a
quasi-stable derepression of the initiated phenotype
is consistent with this, stage I could also be
explained by the selection hypothesis (Yuspa et al.,
1981; 1982; 1983b; see Figure 3).
The first TPA treatment of mouse skin causes
inhibition of DNA synthesis (Raick et al., 1972)
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Figure 3 The role of selection in tumour promotion.
Reiners & Slaga, 1983; Morris et al., 1985)
probably as a consequence of induced terminal
differentiation (see sections 3, 4 and 5). In the
hyperplasia that follows, extensive regeneration of
the epidermis would occur from the stem cell
compartment (including the initiated cells) as
discussed earlier (section 5), and could in some way
release the initiated cell from the repressive effect of
local inhibitory factors (Bell, 1976). In contrast,
there is little inhibition of DNA synthesis (and by
inference basal cell differentiation) associated with
subsequent TPA treatments and the reason for this
is unknown. It may be related to an overall change
in the epidermal cells themselves brought about by
the first TPA treatment causing them to lapse into
a ontogentically more primitive state (Marks et al.,
1982), where the basal layer is taken over by a
chalone insensitiv9 stem cell population (Marks et
al., 1978a, b) that is stimulated to proliferate by
TPA instead of being inhibited (Yuspa et al., 1981;
1982; 1983b). Alternatively, there might be a more
trivial explanation related to the hyperplastic
thickening of the epidermis prior to the second, but
not the first TPA treatment. This would have the
effect of reducing the magnitude, or rate of delivery
of the second dose of TPA, and hence also the
inhibition of DNA synthesis and the induction of
terminal differentiation in the basal layer, whilst
still considerably accelerating differentiation in the
superficial layers which do not synthesise DNA.
This would have the effect of sustaining a
regenerative hyperplasia without prior inhibition of
DNA synthesis. This alternative is supported by the
observation that hyperplasia caused by the later
TPA treatments is still dependent on the synthesis
of prostaglandin E2 and this would not be expected
if TPA was stimulating DNA synthesis without
some prior damage (Marks et al., 1982).
Assuming that the above statements are true then
it is clear that the first clonal expansion after TPA
would be much larger than the subsequent ones as
there would be far more basal cell loss in the
former case, removing any lateral restriction to
expansion of the initiated clones along the
basement membrane. With later treatments the
growth of the papilloma would be restricted to an
upward direction because of the lateral restriction
of the normal basal cells, explaining also the classic
pedunculated shape of these lesions. Such an
argument is also consistent with the observation
that stage I of promotion is much longer lasting
than stage II (Slaga et al., 1980b; Furstenberger et
al., 1983).
To summarise, I am suggesting that in contrast
to TPA, second stage promoters are unable to
cause the initial selective growth from the stem cell
compartment, because they induce terminal
differentiation in all the basal cells equally, unlike
TPA which selectively induces differentiation in the
more mature basal keratinocytes (Parkinson et al.,
1983; Parkinson et al., 1984; Morris et al., 1985).
We suggest also that the initial clonal expansion
leads in some way to the expression of the trans-
formed phenotype. Following this TPA or the
second stage promoters would give transformed
keratinocytes a selective advantage (as in section 4),
Subsequent
TPA treatments
Further permanent
genetic change TPA
independent
Corcinomatous
transformation
Tumourigenic
(subcutaneous
injection)488 E.K. PARKINSON
because when the transformed phenotype is
expressed, keratinocytes are equally refractory to
TPA- or second stage promoter-induced terminal
differentiation (Parkinson et al., 1984).
7. The role of selection in tumour promotion
It was recently shown that more than one oncogene
must be activated in concert to malignantly
transform fibroblasts (Ruley, 1983, Land et al.,
1983, Newbold & Overell, 1983). Initiated cells
contain at least one of the genomic changes
required for keratinocyte malignancy and the
selective clonal expansion of these cells into
papillomas of 105-106 cells (Hennings & Yuspa
1985) would increase the probability that one or
more of the initiated cells will acquire the
remaining changes required to complete
carcinogenesis.
Prior to malignancy papillomas may first acquire
the ability to grow autonomously in the differen-
tiating zone of the epidermis (see section 1, Figure
3) and there is some evidence that complementation
of an activated rasH gene by immortalisation and/or
aneuploidy (Weissman & Aaronson, 1983) allows
keratincoytes to grow under conditions where ras1
activation alone cannot (Yuspa et al., 1983a, 1985).
Cell lines cultured from papillomas also display
both in vitro immortality (Pera & Gorman, 1984)
and an activated rasH gene (M.F. Pera & A.
Balmain - personal communication). An increased
ability to evade senescence when cultured in the
presence of low levels of serum growth factors is a
property associated with fibroblast immortality and
in this cell type a combination of immortalisation
and an activated rasH gene is sufficient to give
malignancy (R.F. Newbold - personal communi-
cations). One could speculate that a reduced
requirement for certain growth factors might also
allow keratinocytes initiated by rasH activation to
grow autonomously in zones of the epidermis where
previously they could not (see Yuspa et al., 1985).
Whether the irreversible change from a promoter-
dependent to a promoter-independent lesion is
spontaneous or whether it involves TPA-induced
chromosome changes (Kinsella & Radman, 1978;
Emeritt & Cerutti, 1981; Parry et al., 1981) or gene
amplications (Varshavsky, 1981) as a possible
consequence of the ability of TPA to generate free
radicals (Troll et al., 1982) awaits the design of
suitable in vivo experiments as far as epidermis is
concerned. It is interesting, however, that TPA
(Colburn et al., 1978 and other free radical
generating compounds (Gindhart et al., 1984) can
induce certain epidermal cell lines to become
irreversibly anchorage independent, and this might
be relevent to the ability of keratinocytes to grow
autonomously even when detached from the
basement membrane. Furthermore, if involved at
all, free radicals are thought to be involved in stage
II of promotion (Schwarz et al., 1984) and the
effect of TPA on anchorage independence is
blocked by both radical scavengers (Nakamura et
al., 1985) and retinoids (Colburn, 1979) the last of
which specifically inhibits stage II promotion (Slaga
et al., 1980a).
Nevertheless since cell lines derived from papillo-
mas (unlike those from carcinomas) are still not
tumourigenic (Pera & Gorman, 1984) it is clear that
a third irreversible event is required to produce
malignancy in keratinocytes in contrast to the
situation with fibroblasts (Newbold & Overell,
1983). This third event may only be necessary in
epithelium because of the constraints placed upon
the tumour cells by the close proximity of normal
cells in this tissue as fully discussed elsewhere by
Balmain (1985), and in mouse skin carcinogenesis
the evidence uniformily suggests that malignant
conversion proceeds independently of TPA once the
maximum papilloma yield has been obtained (Burns
et al., 1978; Verma & Boutwell, 1980; Hennings et
al., 1983).
In this review I have attempted to present
evidence supporting the hypothesis that clonal
selection of the initiated cells (Yuspa et al., 1981) is
important for tumour promotion by TPA and
wounding. It should be stressed however, that these
ideas may not necessarily apply to promoters
6utside the diterpene series (Delclos et al., 1980;
Reiners et al., 1984) or indeed to tissues other than
those capable of cornification. A better assessment
of the arguments put forward in this article will
depend of course upon future developments in
oncogene and growth factor research, but will
also require an improvement in our knowledge of
the keratinocyte cell lineage and in particular its
response to injury.
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